Cost Analysis of Type 1 Diabetes Illness in Terms of Patient Perspectives

Aim: Cost analysis of Type 1 diabetes is important in guiding decision-makers. It aims to guide the decisions of health policy makers by calculating the costs of Type 1 diabetes as total costs and lifetime costs according to patients' perspectives. Method: The study data were obtained from a university hospital information system, expert opinion, fiduciary, Revolving Fund Management Directorate, Health Implementation Communiqué, and hospital records. In this study, the prevalence-based cost analysis method was used. In line with these data, annual total costs per patient and lifetime costs were calculated. Results: It has been observed that the annual cost of out-of-pocket payments incurred by patients is $825.15 per patient for not using an insulin pump, $1,579.77 for using an insulin pump, and $4,732.15 for using a sensor. It has been calculated that it can bear costs. Considering that the average lifespan of a patient is 68.5, the lifetime costs for each patient are $564,851.23 for those who do not use an insulin pump, $1,081,418.94 for those using an insulin pump, and $3,239,447.90 for those who use a continuous blood glucose measurement system. Conclusion: Management of the illness is important for reducing costs. If not controlled, the patient will experience hypoglycemia or hyperglycemia, and costs will increase. The resulting data can be used to evaluate the resource distribution and service efficiency of Type 1 diabetes.